Form 4: Avidity Biosciences CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Avidity Biosciences CEO, Sarah Boyce, sold 31,855 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• Avidity Biosciences CEO, Sarah Boyce, sold 31,855 shares of common stock on December 18, 2024, at a weighted average price of $32.66 per share.
• The sale was triggered by the vesting of 62,500 time-based restricted stock units (RSUs) on December 17, 2024.
• These RSUs were initially granted as performance-based restricted stock units (PSUs) and converted to time-based RSUs after a performance objective was met on June 17, 2024.
• The sale was mandated by the company's equity incentive plan to cover tax withholding obligations, and was not a discretionary trade by the CEO.
• The CEO has an instruction letter for automatic sell-to-cover transactions, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This is a standard practice for executives who receive equity compensation, where a portion of shares are sold to cover tax liabilities upon vesting. It is common in the biotech industry.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies, particularly in the biotech sector where equity compensation is a significant part of executive pay.
• Many companies use similar mechanisms to manage tax obligations for their employees and executives.
• The weighted average price of $32.66 is within the range of recent trading activity for Avidity Biosciences stock.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the nature of the transaction.

Key Dates

Keywords

Avidity Biosciences, Sarah Boyce, stock sale, restricted stock units, RSU, tax obligations, sell-to-cover, insider trading, Rule 10b5-1